Abstract
The availability of two groups of pharmacologic agents, the nucleoside analogs and anti-lymphocyte antibody preparations of various specificities has enabled the development of NST. Although these agents are significantly less cytotoxic than high-dose alkylating agents and total-body irradiation (TBI), they are profoundly immunosuppressive. Opportunistic infections such as the reactivation of cytomegalovirus remain clinical obstacles when NST are performed using these agents, especially in elderly and previously immunosuppressed patients For anti-lymphocyte antibody preparations, the degree of immunosuppression produced and hence the risk of opportunistic infection varies depending upon specificity of the antibody (broad versus narrow). Allergic reactions and infusion related toxicity can occur with any antibody preparation, but the infusion of muromonab-CD3 is sometimes associated with a particularly potent cytokine-release syndrome. Although fludarabine has been the mainstay of nucleoside analog usage for NST, the other nucleoside analogs-cladribine and pentostatin are beginning to be investigated in this context.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adkins JC, Peters DH, Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997;53(6):1005–37.
Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;97(3):631–7.
Kraut EH, Bouroncle BA, Grever MR. Low-dose deoxycoformycin in the treatment of hairy cell leukemia. Blood 1986;68(5):1119–22.
Grever MR, Leiby JM, Kraut EH, et al. Low-dose deoxycoformycin in lymphoid malignancy. J Clin Oncol 1985;3(9):1196–201.
Margolis J, Vogelsang G. An old drug for a new disease: pentostatin (Nipent) in acute graft-versus-host disease. Seminars in Oncology 2000;27(2 Suppl 5):72–7.
Amado RG, Schiller GJ. Nonmyeloablative approaches to the treatment of sickle hemoglobinopathies. Seminars in Oncology 2000;27(2 Suppl 5):82–9.
Ekberg H, Kallen R, Schatz H, Persson NH. Low-dose ATGAM treatment sufficiently reduces total T-cell counts and remains clinically effective in prophylactic and anti-rejection protocols. Transplant Proc 1995;27(6):3430–1.
Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998;66(1):29–37.
Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients [published erratum appears in Transplantation 1999 May 27;67(10):1386]. Transplantation 1999;67(7):1011–8.
Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000;95(1):83–9.
Dyer MJ. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Seminars in Oncology 1999;26(5 Suppl 14):52–7.
Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000;96(7):2419–25.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bashey, A. (2002). Immunosuppression with Limited Toxicity: The Characteristics of Nucleoside Analogs and Anti-Lymphocyte Antibodies Used in Nonmyeloablative Hematopoietic Cell Transplantation. In: Bashey, A., Ball, E.D. (eds) Non-Myeloablative Allogeneic Transplantation. Cancer Treatment and Research, vol 110. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0919-6_2
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0919-6_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5304-1
Online ISBN: 978-1-4615-0919-6
eBook Packages: Springer Book Archive